AMCASERTIB |
BBI503 | 1129403-56-0 | Antineoplastic | Boston Biomedical, Inc. | View |
TOREFORANT |
JNJ-38518168 | 952494-46-1 | Treatment of asthma, psoriasis | Janssen Research & Development LLC | View |
RINUCUMAB |
REGN2176 | 1569263-06-4 | Treatment of neovascular age-related macular degeneration | Regeneron Pharmaceuticals, Inc. | View |
TECEMO-TIDE |
BLP25 | 221214-84-2 | Antineoplastic | EMD Serono | View |
LOTRAFILCON A |
| 203170-33-3 | contact lens material (hydrophilic) | Ciba Vision Corporation | View |
NASARUPLASE BETA |
Abbott-74187; ABT-187 | 136653-69-5 | treatment of acute ischemic stroke | Abbott Laboratories | View |
FOSVESET |
texaphyrin, Gd-Tex, FP-GP1, API-GP3 | 193901-91-6 | ligant excipient | Mallinckrodt Inc. | View |
MOTEXAFIN GADOLINIUM |
PCI-0120; gadolinium texaphyrin, Gd | 156436-89-4 | antineoplastic | Pharmacyclics, Inc. | View |
MOTEXAFIN LUTETIUM |
PCI-0123; lutetium texaphyrin, Lu
texaphyrin, Lu-Tex; FP-LP1 | 156436-90-7 | antineoplastic/antiatherosclerotic | Pharmacyclics, Inc. | View |
PEGINTERFERON ALFA-2a |
Ro 25-8310/000 | 198153-51-4 | treatment of hepatitis C | Hoffmann-La Roche, Inc. | View |
RESLIZUMAB |
SCH 55700 | 241473-69-8 | treatment of bronchial asthma as well as a pharmacological tool to elucidate the role of IL-5 in human eosinophilic diseases | Schering-Plough Corporation | View |
TROSPIUM CHLORIDE |
IP631 | N/A | treatment of urinary incontinence | Maudaus, AG, Germany | View |
ZONIPORIDE MESYLATE |
CP-597,396-27 | 249296-45-5 | cardioprotective ((Na+-H+ exchanger-1 NHE-1) inhibitor)) | Pfizer, Inc. | View |
ROSUVASTATIN CALCIUM |
ZD4522; S-4522 | 147098-20-2 | antihyperlipidemic (HMGCoA reductase inhibitor) | AstraZeneca Pharmaceuticals LP | View |
ENFUVIRTIDE |
T20; DP178 | N/A | antiviral (blockade of gp-41 mediated membrane fusion) | Trimeris, Inc.; Roche Colorado Corp. | View |
AMOTOSALEN HYDROCHLORIDE |
S-59 | 161262-45-9 | photochemical treatment (light-activated psoralen derivative intended for use in the inactivation of viruses, bacteria, and leukocytes in platelet concentrates and fresh frozen plasma in blood bank settings) | Cerus Corporation | View |
ERTAPENEM SODIUM |
MK-0826 | 153832-38-3 | antibacterial | Merck & Co., Inc. | View |
INGLIFORIB |
CP-368,296 | 186392-65-4 | treatment of type 2 diabetes mellitus (glycogen phosphorylase inhibitor) | Pfizer Inc. | View |
DIBOTERMIN ALFA |
| 246539-15-1 | osteoinductive agent for use in orthopaedic surgery, dental/craniofacial surgery, or spine surgery, as an adjunct to standard care or as a replacement for autogenous bone graft | Wyeth | View |
PEXELIZUMAB |
h5G1.1 scFv; h5G1.1 scFv (CDR) | N/A | complement inhibitor used to reduce the impact of complement-mediated injuries sustained during cardiopulmonary bypass (humanized monoclonal antibody) | Alexion Pharmaceuticals, Inc. | View |